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Methods and results. We found that a sizeable portion of Th17 cells express HIV coreceptor CCR5 and produce very low levels of CCR5 ligands macrophage inflammatory protein (MIP)-1a and MIP-1b. Accordingly, CCR5 + Th17 cells were efficiently infected with CCR5-tropic HIV and were depleted during viral replication in vitro. Remarkably, HIV-infected individuals receiving treatment had significantly reduced Th17 cell counts, compared with HIV-uninfected subjects, regardless of viral load or CD4 cell count, whereas treatment-naive subjects had normal levels. However, there was a preferential reduction in CCR5 + T cells that were also CCR6 positive, which is expressed on all Th17 cells, compared with CCR6
Ϫ CCR5 + cells, in both treated and untreated HIV-infected subjects. This observation suggests preferential targeting of CCR6 + CCR5
+ Th17 cells by CCR5-tropic viruses in vivo. Th17 cell levels also inversely correlated with activated CD4 + T cells in HIV-infected individuals who are receiving treatment. Conclusions. Our findings suggest a complex perturbation of Th17 subsets during the course of HIV disease potentially through both direct viral infection and virus indirect mechanisms, such as immune activation.
Th17 cells, a subset of helper T cells, mediate inflammation [1] and development of autoimmunity [2] [3] [4] [5] [6] [7] . Th17 cells are also important in protective immune responses to a variety of pathogens in animal models [8] [9] [10] [11] [12] [13] . In humans, it was recently reported that patients with hyper immunoglobulin E syndrome, char-acterized by recurrent Staphylococcus and Candida infections [14, 15] , have impaired Th17 development [16, 17] , further highlighting the importance of Th17 responses in normal host defense against these pathogens.
Human immunodeficiency virus (HIV) infection perturbs T cell subsets [18] , and the systemic depletion of CD4 + T cells leads to immunosuppression and development of opportunistic infections, such as Pneumocystis jiroveci and Candida infection [19] . Several groups have also reported the depletion of mucosaassociated memory CD4 + CCR5
+ T cells and linked this to HIV disease progression [20] [21] [22] . HIV-infected patients also have higher levels of chronic immune activation markers, which correlate with disease progression and CD4 + cell depletion [23, 24] . Th17 cells could play a role in host defense mechanisms against HIVassociated opportunistic infections [11, 13] . Th17 cells are also enriched in the lamina propria of the gastrointestinal tract [25, 26] and may play an important role in the defense against microbes, particularly at mucosal surfaces [27] . Thus, perturbation of Th17 cells during у60  37  239  1090  у60  38  686  4990  Naive  39  336  21,900  Naive  40  332  100,000  Naive  41  418  24,300  Naive  42  476  100,000  Naive  43  567  33,000  Naive  44  104  70,600  Naive  45  617  721  Naive  46  652  23,300  Naive  47  322  10,800  Naive  48  188 15,700 Naive HIV infection could compromise mucosal defenses against resident and pathogenic microbes, which, in turn, could result in immune activation [28] .
Little is known about the role of Th17 cells in HIV pathogenesis. Two recent studies of Th17 cells in HIV infection showed that HIV-infected children with detectable virus loads had lower levels of interleukin (IL)-17-secreting cells than did HIV-uninfected children [29] , and in adults, Th17 cells were lost in the gastrointestinal tract of HIV-infected individuals [30] . However, another cross-sectional study suggested significantly higher levels of IL-17 in HIV-infected individuals, compared with HIV-uninfected volunteers [31] . It is also not clear whether Th17 cells are directly infected and depleted by HIV or whether their numbers are perturbed due to generalized immune activation.
Here we sought to determine the susceptibility of Th17 subsets to CCR5-tropic (R5-tropic) HIV infection and the relative proportion of these effector cells in HIV-infected individuals. We found that a sizeable portion of Th17 cells expressed CCR5 and low levels of CCR5 ligands macrophage inflammatory protein (MIP)-1a and MIP-1b and were highly susceptible to infection with R5-tropic viruses. Th17 cells were reduced in the blood of HIV-infected individuals who were receiving antiretroviral therapy (ART) but not in untreated (ie, treatmentnaive) subjects, compared with HIV-uninfected subjects. Remarkably, reduction in the number of Th17 cells in HIV-infected individuals receiving ART with undetectable viral load was highly correlated with increased immune activation parameters, suggesting this may be a potential reason for perturbation of Th17 cells in this group of patients.
MATERIALS AND METHODS

Subjects.
Thirty-seven ART-receiving and 11 treatment-naive HIV-infected individuals were recruited in accordance with an institutional review board-approved protocol and consent. The HIV loads were determined by HIV RNA polymerase chain reaction (PCR), with the results reported as the number of copies per milliliter. Clinical details for each subject are shown in Table 1 . HIV-infected individuals who were receiving ART had a median CD4 count of 336 cells/mm 3 . Twenty-six patients who were receiving ART had an HIV load !50 copies/mL, and the remaining had a median HIV load of 997 copies/mL. Treatment-naive HIV-infected individuals had a median HIV load of 23,300 copies/mL and a median CD4 cell count of 418 cells/ mm 3 , which was not statistically different from the CD4 cell counts of HIV-infected individuals who were receiving ART. For HIV-uninfected controls, 33 random blood samples were obtained from the blood bank.
Staining and fluorescence-activated cell sorting analysis. Cells were stained with corresponding antibodies, as previously described [32] . For intracellular staining, fixation and permeabilization were performed using a kit (BD Biosciences) in accordance with the manufacturer's instructions. Analyses were performed using LSRII flow cytometer (BD Biosciences) and FlowJo software (Tree Star). The following anti-human antibodies were used for staining: CD3, CD25, CD38, CD45RO, CCR5, CCR6, MIP-1a, MIP-1b, (BD Biosciences), CD4, CD8, interferon (IFN)-g, and IL-17 (eBioscience). Intracellular HIV p24 staining was done using phycoerythrin-conjugated p24 antibody (Coulter), as described above. Chemokine secretion was measured from T cells activated with plate-bound anti-CD3 and soluble anti-CD28 for 16 h using a cytometric bead array (BD Biosciences).
HIV production. HIV pseudotyped with vesicular stomatitis virus (VSV)-G envelope (VSV-G.HIV) was generated as described elsewhere [33] . Viral supernatants from replication competent CCR5-tropic HIV were prepared by transfecting HEK293T cells with HIV that encoded R5-tropic (BaL) envelope. These viruses expressed either murine CD24 (mCD24) or green fluorescent protein (GFP) in place of the nef gene as marker genes, as described elsewhere [32] [33] [34] . In some experiments R5-tropic viruses that also encode nef were used and the infections were monitored by intracellular p24 staining as described elsewhere [32] [33] [34] . Viral titers were measured as described elsewhere [32, 33] and ranged from to 6 10 ϫ 10 infectious units/mL for replication-competent viruses 6 5 ϫ 10 and 10-infectious units/mL for VSV-G.HIV. 6 30 ϫ 10 T cell purifications. Peripheral blood mononuclear cells from the blood of HIV-uninfected and HIV-infected individuals were prepared using Ficoll-paque plus (GE Health care). CD4 + T cells were isolated using Dynal CD4 Positive Isolation Kit (Invitrogen) and were 199% pure. CD4 + cells from healthy donors were further sorted by flow cytometry (FACSAria; BD Biosciences) on the basis of expression of CD45RO and CCR6 or CCR5 and were used for the in vitro experiments. Sorted subsets were 199% pure and were kept at 37ЊC and 5% CO 2 in Roswell Park Memorial Institute 1640 medium with 10% fetal calf serum [32] .
T cell activation and HIV infection. Sorted CD4 + T cell subsets were stimulated and maintained in IL-15 (10 ng/mL; R&D Systems) during the course of infection experiments. Five days later, cells were infected with VSV-G.HIV, or R5.HIV at different multiplicities of infection. Alternatively, cells were activated with anti-CD3/CD28 conjugated beads. For intracellular cytokine or chemokine staining, cells were reactivated for 5 h with Phorbol ester (20 ng/mL; Sigma), ionomycin (500 ng/mL; Sigma), and GolgiStop (Brefeldin A; BD Biosciences) to prevent protein secretion.
Statistical analysis. All statistical analyses were performed with GraphPad Prism software, version 5.0 (GraphPad Software). The significance in in vitro studies was determined using a 2-tailed 2-sample Student t test. Comparisons of HIV-infected and HIV-uninfected individuals were analyzed using the MannWhitney U test, and the results were considered statistically significant if the P value was !.05. Correlation between IL-17, IFN-g, and T cell activation markers was calculated by the Spearman rank test.
RESULTS
Expression of HIV coreceptor CCR5 on Th17 cells. Human Th17 cells are part of the CD4
+ memory subset and have been reported to express the chemokine receptor CCR6 [8, 35, 36] . Infection with R5-and X4-tropic HIV requires expression of CCR5 or CXCR4, respectively, in addition to CD4. We found that a sizeable and significantly higher proportion of CCR6 + T cells than the CCR6 Ϫ subset, expressed CCR5, which is in contrast to another recent study [37] . The expression of CXCR4 was high and similar in both subsets ( Figure 1A and 1B). CD45RO + memory cells were then sorted into 4 subsets on the basis of these chemokine receptor profiles shown in Figure 1C : Ϫ T cells from healthy individuals were sorted and activated as described in the methods section. These cells were then stained for intracellular IL-17 and IFN-g in conjunction with MIP-1a and MIP-1b ( Figure 2A ). We found that Th17 cells produced significantly less of either chemokine than did IFN-g + T cells, both in CCR6 + and CCR6 Ϫ subsets ( Figure   2B ). This finding suggests that the Th17 T cell subset would be predicted to have less capability to suppress CCR5-mediated HIV entry through chemokine expression during T cell activation. HIV infection of Th17 cells. On the basis of the findings above, we then determined the susceptibility of Th17 cells to HIV infection. T cells require activation either through the T cell receptor (TCR) or via cytokines to become susceptible to HIV [33] . For this purpose, we stimulated sorted memory CCR6 + and CCR6 Ϫ cells either through the TCR or via IL-15 alone, which renders resting T cells susceptible to infection [33] and enhances the production of IL-17 [39] . Cells stimulated with IL-15 displayed 3 effector subsets (ie, IL-17
+ subsets) after 6-day culture in vitro ( Figure 3A ) and maintained this for up to 3 weeks in culture (data not shown). Th17 cells were not induced in the CCR6 Ϫ subset with either stimulus ( Figure 3A) .
In subsequent experiments, we focused on using IL-15 stim- ulation to determine susceptibility of Th17 subsets to HIV infection, because we found that activation of T cells through the TCR, as opposed to IL-15, causes extensive proliferation of T cells, which skews IL-17-secreting effector populations in vitro from experiment to experiment. Furthermore, the TCR activation-induced differentiation and proliferation also occasionally selected for cells that could have differential susceptibility to HIV, possibly in association with changes in receptor expression or chemokine secretion, whereas IL-15 activation of resting T cells has minimal effect on T cell proliferation while still rendering them susceptible to HIV. Therefore, we challenged CCR6 + memory T cells cultured in the presence of IL-15 with either replication-incompetent VSV-G-pseudotyped HIV (VSV-G.HIV), which bypasses a receptor requirement, or with replication-competent R5-tropic HIV (R5.HIV). We found that IL-15 stimulation rendered Th17 cells susceptible to infection with both viruses ( Figure 3B) .
The IL-15-stimulated and HIV-infected T cells were then harvested every 3 days and evaluated for GFP expression as a marker for infected T cells and stained for IL-17 and IFN-g to monitor the changes of effector cells in the cultures. We found that, although IFN-g + and IL-17 + subsets were similarly infected with R5.HIV or VSV-G.HIV (Figure 3C ), the IFN-g + IL-17 + T cells were relatively more susceptible with R5.HIV and VSV-G.HIV, compared with the other 2 subsets of T cells ( Figure  3C ). Of interest, CCR6
Ϫ T cells that were IFN-g + were significantly less susceptible to HIV infection both with R5.HIV as well as VSVG.HIV compared to CCR6 + IFN-g + T cells ( Figure  3D ). On the basis of this result, we hypothesized that T cell subsets infected with replicating HIV would also be preferen- + T cells stained with CD45RO and CCR6 antibodies and sorted into CD45RO + CCR6 + and CD45RO + CCR6 Ϫ . Purified cells were cultured in IL-15 for 5 days or were activated using anti-CD3/CD28 conjugated beads. Intracellular staining for interferon (IFN)-g and IL-17 was performed at day 6 post activation as described in Figure 1 . Figure 5A ). Similarly IFN-g-secreting cells were also significantly lower in HIV-infected groups regardless of the CD4 + cell numbers ( Figure 5A ). There was no correlation between total CD4 cell counts and either IL-17 + or IFN-g + T cell counts (data not shown). We next compared the HIV-infected population on the basis of antiretroviral treatment and HIV load. All treatment-naive subjects had HIV loads 150 copies/mL, by determined by HIV RNA PCR. The subjects who were receiving ART were further divided by HIV load !50 copies/mL or у50 copies/mL. Remarkably, the portion of IL-17 + and IFN-g + IL-17 + T cells in treatment-naive subjects was not significantly different from that in the HIV-uninfected subjects ( Figure 5B ). This observation was confirmed even when we calculated the absolute cell numbers of each cytokine-producing subset in which we did not find significant difference between absolute cell counts of IL-17 + and IFN-g values-both in percentages ( Figure 5B ) and, more significantly, in absolute numbers ( Figure 5C ). All HIV-infected individuals had significantly fewer IFN-g + -producing cells, regardless of ART therapy and HIV load ( Figure 5B ).
Since one would predict that R5-tropic viruses would preferentially deplete CCR5 + T cells, we hypothesized that there would be fewer CCR5 + Th17 cells in HIV infected individuals. Because it was difficult to measure CCR5 expression in conjunction with IL-17 staining due to transient downregulation of CCR5 after activation and lower sensitivity during intracellular staining (data not shown), we determined the percent of memory CCR5
+ T cells as well as the percent of CCR5 + cells within the CCR6 + subset, since all Th17 cells express the latter marker. HIV-infected subjects overall had lower CCR5 + memory cells both in naive and ART HIV-infected subjects ( Figure  6A) . Interestingly, the total proportion of CCR6 + cells was significantly increased in both naive and ART groups compared to HIV-uninfected subjects ( Figure 6A ). In contrast, CCR5 + within CCR6 + T cells were greatly reduced in both HIV-infected groups, (Figure 6B ), whereas the proportion of CCR5 + within CCR6 Ϫ T cells was not different compared to healthy donors ( Figure 6B ). Taken together, these findings demonstrate a preferential reduction in the proportion of CCR5 + CCR6 + memory T cells in vivo in HIV-infected individuals, which may be a consequence of direct infection and depletion with R5-tropic HIV due to high susceptibility of these cells to infection.
Despite T cell depletion, it is well known that HIV-infected individuals demonstrate evidence of chronic immune activation. Consistent with prior studies, HIV-infected individuals had significantly higher expression of immune activation marker CD38 within CD4 + T cells, ( Figure 6C and 6D) , an independent predictor of disease progression [40, 41] . Remarkably, in the group of HIV-infected individuals who were receiving ART and who had undetectable HIV RNA levels, the reduction in IL-17 correlated positively with the percentage of CD4 + CD38 + cells ( Figure 6E ). A similar correlation was seen between CD4 + CD38 + cells and IFN-g-secreting cells. There was no statistical correlation between CD4 + CD38 + T cells and IL-17-or IFN-g-secreting cells both in HIV-negative individuals ( Figure 6E ) and in HIV-infected individuals who were treatment naive or who were receiving ART and who had HIV RNA levels у50 copies/mL (data not shown).
DISCUSSION
Our findings that a portion of Th17 cells express high levels of CCR5 and lower levels of CCR5 ligands MIP-1a and MIP1b, correlated with a high infection rate of this subset with R5-tropic HIV. This finding suggests that CCR5 + Th17 cells are conceivably infected with HIV in vivo and provide an explanation for their preferential depletion in the gut of HIV-infected patients [30] . Interestingly, we found that infection and deple- + cells were also more susceptible to VSV-G-pseudotyped HIV, suggesting post-entry intrinsic host factors that modulate HIV infection of this subset compared to other effector T cell subsets. More detailed characterization of this subset including their phenotypic profile and effector functions might give us clues as to their origin and function in normal immune responses as well as their role in HIV pathogenesis.
Variations in MIP-1a gene dose and CCR5 genotypes were shown to act as host factors that affect HIV transmission, viral load, disease progression and immune recovery during antiretroviral therapy. In fact, the gene encoding MIP-1a encompasses many segmental duplications and people with a copy number of the MIP-1a gene lower than the population average have markedly enhanced HIV/AIDS susceptibility [42, 43] . It will be interesting in the future to determine the level of Th17 cells in these individuals with genetic differences in their CCR5 ligand levels or expression.
We showed here that HIV targets Th17 cells in in vitro experiments, which predicted that they would be depleted preferentially in subjects with higher viral loads. However, we found that Th17 subsets, along with IFN-g + T cells, were greatly reduced in HIV-infected subjects who were receiving treatment and even with undetectable viremia. It was also puzzling that in treatment-naive HIV-infected individuals there was no decrease in IL-17 + T cells. How then can our results showing in vitro HIV-susceptibility of Th17 cells be reconciled with these perplexing ex vivo findings? We think during early stages of infection, Th17 cells are indeed targeted by HIV in vivo, but one would expect only the CCR5 + Th17 subset to be susceptible to infection with R5-tropic viruses. Indeed we found a dramatic decrease in the CCR5 + portion of CCR6 + T cells both in treatment-naive subjects and in ART recipients ( Figure 6B ). This finding is also consistent with a recent report describing preferential and rapid depletion of Th17 cells in the gut mucosa of HIV-infected individuals, which would be expected to be mostly CCR5 positive [30] . We postulate that perhaps the relative decrease in CCR5 + CCR6 + T cells, which contain a substantial portion of the Th17 subset, causes a perturbation that results in a compensatory increase in CCR5 Ϫ Th17 cells in naive HIV-infected subjects. In addition, although naive subjects in our study may not have reached their nadir CD4 cell counts, some of the ART subjects could have started with a lower nadir CD4 cell count prior to initiation of ART. It is conceivable that as CD4 + T cells progressively decline during the course of HIV infection, Th17 cells are depleted, and ART treatment may fail to restore their levels once lost to preinfection levels, perhaps because of a compromise in Th17 cell differentiation or sur- vival. However, because our study was not longitudinal, it is difficult to predict when during the course of HIV infection this decline occurs and whether antiretroviral therapy restores Th17 cells. An alternative possibility is that, IL-17 as a marker underestimates the presence of lineage committed Th17 cells. It is conceivable that constant immune activation or immuneexhaustion suppresses Th17 or Th1 cells from displaying their effector functions such as secretion of IL-17 and IFN-g. In support of this notion of immune-exhaustion, Nixon and colleagues recently showed that a molecule called Tim-3 is upregulated in chronically activated T cells in HIV-infected subjects and that these cells did not secrete IFN-g unless the signals from Tim-3 were blocked by neutralizing its interaction with its ligand [44] . It will be interesting to determine in future studies whether secretion of IL-17 can also be rescued by suppressing Tim-3 or other negative signaling molecules such as PD-1 on CCR6 + T cells.
How could reduced levels of IL-17-secreting cells impact HIV pathogenesis? A potential scenario can be envisaged, where the loss of Th17 cells may compromise the mucosal immune system during HIV infection. Th17 cells assist in vivo in mucosal host defense against many pathogens in the gut, lungs and skin through regulating antimicrobial peptide production by epithelial cells and keratinocytes [27, 45] . The loss of Th17 cells during HIV infection might also contribute to microbial translocation of bacterial products from mucosal tissues to the circulation resulting in immune activation [28, 46] . Hence, the loss of Th17 cells during HIV infection could also potentially be a biomarker for disease progression. More studies will be needed to understand the impact of Th17 depletion in HIV pathogenesis and its relationship with other T cell subsets, such as regulatory T cells. Future prospective studies will also be important to determine if Th17 cells decline immediately posttreatment of naive subjects and whether Th17 cells are reconstituted when immune activation is subdued.
In conclusion, we have shown that Th17 cells represent ideal targets for HIV by virtue of high expression of CCR5 and lower secretion of CCR5 ligands MIP-1a and MIP-1b. The high susceptibility of Th17 cells to HIV in vitro was reflected by their in vivo depletion in the peripheral blood of HIV-infected individuals. Association of this preferential depletion with immune activation was particularly striking and highlights the potential significance of Th17 cell depletion during HIV immunopathogenesis.
